- $40.52m
- $22.11m
- $0.05m
Brief: Inmune Bio Completes Blinded Interim Analysis Of Phase II Alzheimer's Disease Trial
INmune Bio Inc expected to post a loss of 53 cents a share - Earnings Preview
Brief: Inmune Bio Inc Files For Mixed Shelf Offering Of Up To $250 Million - SEC Filing
INmune Bio Inc expected to post a loss of 53 cents a share - Earnings Preview
Brief: INmune Bio Announces $9.7 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
INmune Bio Inc reports results for the quarter ended in December - Earnings Summary
Brief: INmune Bio Reports EEG Improvement In Alzheimer’s Patients Treated with XPro
INmune Bio Inc expected to post a loss of 44 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP- Advanced Micro Devices, HCA Healthcare, Vertex Pharmaceuticals
Brief: Inmune Bio Under Deal Elevai Will Make An Initial Deposit For License In Two Installments Over Six Months
U.S. STOCKS ON THE MOVE-Rockwell Automation, Crinetics Pharmaceuticals, TransUnion
U.S. STOCKS ON THE MOVE-Arvinas, FMC Corp, Wave Life Science
INmune Bio falls after Alzheimer's drug trial to remain on hold in US
INmune Bio falls after mid-stage trial for Alzheimer's drug to remain on hold
Brief: Inmune Bio Updates On Alzheimer’S Phase II Clinical Trial And Clinical Hold Issued By FDA
Brief: INmune Bio Receives EMA Authorization In France And Spain For Phase II Clinical Trial Of XPro For Early Alzheimer’s Disease
Brief: INmune Bio Announces Expansion Of Phase II Clinical Trial For Alzheimer’S Disease In Europe
INmune Bio Inc reports results for the quarter ended in September - Earnings Summary
Brief: INmune Bio Inc. Patent Claims Covering Inb16 Cell Line And Inkmune Therapeutic Composition Given Favorable Patentability Opinion By International Search Authority